Platelet activating factor causes hyperconstriction at the inflammatory coronary lesions in pigs in vivo

Coronary Artery Disease

Volumn 8, Issue 7, 1997, Pages 423-432

  Kozai, Toshiyuki ^a   Shimokawa, Hiroaki ^a   Yamawaki, Tohru ^a   Fukumoto, Yoshihiro ^a   Kadokami, Toshiaki ^a   Kuwata, Kouichi ^a   Katsumata, Naoki ^a   Egashira, Kensuke ^a   Takeshita, Akira ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Coronary artery spasm; Cytokine; Inflammation; Platelet activating factor; Protein kinase C

Indexed keywords

3 BROMO 5 [N PHENYL N [2 [[2 (1,2,3,4 TETRAHYDRO 2 ISOQUINOLYLCARBONYLOXY)ETHYL]CARBAMOYL]ETHYL]CARBAMOYL] 1 PROPYLPYRIDINIUM NITRATE; HISTAMINE; INDOMETACIN; INTERLEUKIN 1BETA; PROSTAGLANDIN F2 ALPHA; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RYANODINE; SEROTONIN; SPHINGOSINE; STAUROSPORINE; THAPSIGARGIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ANGIOCARDIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; INFLAMMATION; LEFT CORONARY ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; SWINE;

EID: 0030775795     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199707000-00004     Document Type: Article

References (39)

1. Maseri A, Severi S, DeNes DM, L'Abbate A, Chierchia S, Marzilli M, et al.: 'Variant' angina: one aspect of a continuous spectrum of vasospastic myocardial ischemia: pathogenetic mechanisms, estimated incidence and clinical and coronary angiographic findings in 138 patients. Am J Cardiol 1978, 42:1019-1035.
2. Hills LD, Braunwald E: Coronary artery spasm. N Engl J Med 1978, 229:695-702.
3. Shepherd JT, Vanhoutte PM: Spasm of the coronary arteries: causes and consequences (the scientist's viewpoint). Mayo Clin Proc 1985, 60:33-46.
4. Fusler V, Vadimon L, Vadimon JJ, Chesebro JF: The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992, 326:242-250.
5. Shimokawa H, Tomoike H, Nabeyama S, Yamamoto H, Araki H, Nakamura M, et al.: Coronary artery spasm induced in atherosclerotic miniature swine. Science 1983, 221:560-562.
6. Shimokawa H, Tomoike H, Nabeyama S, Yamamoto H, Ishii Y, Tanaka K, et al.: Coronary artery spasm induced in miniature swine: angiographic evidence and relation to coronary atherosclerosis. Am Heart J 1985, 10:300-310.
7. Ito A, Shimokawa H, Nakaike R, Fukai T, Sakata M, Takayanagi T, et al.: Role of protein kinase C-mediated pathway in the pathogenesis of coronary artery spasm in a swine model. Circulation 1994, 90:2425-2431.
8. Shimokawa H, Ito A, Fukumoto Y, Kadokami T, Nakaike R, Sakata M, et al.: Chronic treatment with interleukin-1β induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. J Clin Invest 1996, 97:769-776.
9. Ito A, Shimokawa H, Kadokami T, Fukumoto Y, Owada MK, Shiraishi T, et al.: Tyrosine kinase inhibitor suppresses coronary arteriosclerotic changes and vasospastic responses induced by chronic treatment with interleukin-1β in pigs in vivo. J Clin Invest 1995, 96:1288-1294.
10. Kadokami T, Shimokawa H, Fukumoto Y, Ito A, Takayanagi T, Egashira K, et al.: Coronary artery spasm does not depend on the intracellular calcium store but is substantially mediated by the protein kinase C-mediated pathway in a swine model with interleukin-1β in vivo. Circulation 1996, 94:190-196.
11. Ito A, Shimokawa H, Fukumoto Y, Kadokami T, Nakaike R, Takayanagi T, et al.: The role of fibroblast growth factor-2 in the vascular effects of interleukin-1β in porcine coronary arteries in vivo. Cardiovasc Res 1996, 32:570-579.
12. Fukumoto Y, Shimokawa H, Kozai T: Role of tyrosine kinase in the coronary geometric remodeling and the alterations in the myosine heavy chain isoforms induced by chronic treatment with interleukin-1β in vivo. Circulation 1996, 94 (suppl 1):I465.
13. Koltai M, Hosford D, Guinot P, Esanu A, Braquet P: Platelet activating factor (PAF). A review of its effects, antagonists and possible future. Clinical implications (part I). Drugs 1991, 42:9-29.
14. Summers JB, Albert DH: Platelet activating factor antagonists. Adv Pharmacol 1995, 32:67-168.
15. Leli R, Burke JA, Guo ZG, Hattori Y, Hoppens CM, McManus LM, et al.: Acetyl glyceryl ether phosphorylcholine (AGEPC): A putative mediator of cardiac anaphylaxis in the guinea pig. Circ Res 1984, 54:117-122.
16. Stewart IG, Piper PG: Platelet-activating factor induced vasoconstriction in rat isolated perfused hearts: contribution of cyclooxygenase and lipoxygonase arachidonlc acid metabolites. Pharmacol Res Commun 1986, 18:163-172.
17. Stahl G, Lefer DJ, Lefer AM: PAF-acether induced cardiac dysfunction in the isolated perfused guinea pig heart Naunyn Schmiedebergs Arch Pharmacol 1987, 336:459-463.
18. Hu W, Choy PC, Man RYK: Characterization of the coronary vascular responses to platelet-activating factor in the isolated perfused heart Lipids 1991, 26:700-704.
19. Feuerstein G, Boyd LH, Ezra D, Goldstein RE: Effect of platelet-activating factor on coronary circulation of the domestic pig. Am J Physiol 1984, 246:H466-H471.
20. Jackson CV, Schumacher WA, Kunkel SL, Drissol EM, Pope TK, Lucchesi BR, et al.: Platelet-activating factor and the release of a platelet-derived coronary artery vasodilator substance in the canine. Circ Res 1986, 58:218-229.
21. Kita M, Ohmoto Y, Hirai Y, Yamaguchi N, Imanishi J: Induction of cytokines in human peripheral blood mononuclear cells by mycoplasmas. Microbiol Immunol 1992, 36:507-516.
22. Montrucchio G, Alloatti G, Tetta C, De Luca R, Saunders RN, Emanuelli G, et al.: Release of platelet-activating factor from ischemic-reperfused rabbit heart. Am J Physiol 1989, 256:H1236-H1246.
23. Takatani M, Maezaki N, Imura Y, Terashita X, Nishikawa K, Tsushima S: Platelet activating factor (PAF) antagonists: development of a highly potent PAF antagonist, TCV-309. Adv Prostagland Thrombox Leukotr Res 1990, 21:943-946.
24. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (Lond) 1993, 302:801-809.
25. Kohchi K, Takebayashi S, Hiroki T, Nobuyoshi M: Significance of adventitial inflammation of the coronary artery in patients with unstable angina: results at autopsy. Circulation 1985, 71:709-716.
26. Forman MB, Oates JA, Robertson D, Robertson RM, Roberts LJ II, Virmani R: Increased adventitial mast cells in a patient with coronary spasm. N Engl J Med 1985, 313:1138-1141.
27. Kolodgie FD, Virmani R, Cornhill JF, Herderick EE, Smialek J: Increase in atherosclerosis and adventitial mast cells in cocaine abusers: an alternative mechanism of cocaine-associated coronary vasospasm and thrombosis. J Am Coll Cardiol 1991, 17:1553-1560.
28. Mazzone A, De Servi S, Ricevuti G, Mazzucchelli I, Fossati G, Pasotti D, et al.: Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery disease. Circulation 1993, 83:358-363.
29. Libby P: Molecular bases of the acute coronary syndromes. Circulation 1995, 91:2844-2850.
30. Falk E, Prediman K, Shah K, Fuster V: Pathogenesis of plaque disruption. In Atherosclerosis and Coronary Artery Disease. Edited by Fuster R, Ross R, Topol EJ. Philadelphia, PA: Lippencott-Raven Publishers; 1996:491-507.
31. McFadden EP, Clarke JG, Davies GJ, Ksaki JC, Haider AW, Maseri A: Effect of tntracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. N Engl J Med 1991, 324:648-654.
32. Golino P, Piscione F, Willerson JT, Cappelli-bigazzi M, Focaccio A, Villari B, et al.: Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N Engl J Med 1991, 324:641-648.
33. Shukla SD, Hanahan DJ: An early transient decrease in phosphatidyl-inositol 4,5-bisphosphate upon stimulation of rabbit platelets with acetylglycerylether phosphorylcholine (platelet activating factor). Arch Biochem Biophys 1983, 227:626-629.
34. MacIntyre DE, Pollock WK: Platelet-activating factor stimulates phosphatidylinositol turnover in human platelets. Biochem J 1983, 212:433-437.
35. Verghese MW, Charles L, Jakoi L, Dillon SB, Snyderman R: Role of a guanine nucleotide regulatory protein in the activation of phospholipase C by different chemoattractants. J Immunol 1987, 138:4374-4380.
36. Nakashima S, Suganuma A, Sato M, Tohmatsu T, Nozawa Y: Mechanism of arachidonic acid liberation in platelet-activating factor-stimulated human polymorphonuclear neutrophils. J Immunol 1989, 143:1295-1320.
37. McManus LM, Hanahan DJ, Pinckard RN: Human platelet stimulation by acetyl glyceryl ether phosphorylcholine. J Clin Invest 1981, 67:903-906.
38. Sugatani J, Hanahan DJ: Characterization of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (AGEPC)-induced protein phosphorylation in rabbit platelets. Inhibitory effects of AGEPC analogs. Arch Biochem Biophys 1986, 246:855-864.
39. O'Flaherty JT, Hishihira J: Arachidonic metabolites, platelet-activating factor, and the mobilization of protein kinase C in human polymorphonuclear neutrophils. J Immunol 1987, 138:1889-1895.